



Wyoming
Department
of Health

Division of Healthcare Financing

Medicaid Pharmacy News

Dear Providers:

February 18, 2016

GUANFACINE ER WILL NOW BE PREFERRED OVER BRAND INTUNIV

Effective February 8, 2016, Wyoming Medicaid will now prefer the generic guanfacine ER over the brand name Intuniv. Please note that a prior authorization must still be submitted to ensure the client meets the following criteria:

- Must have a diagnosis of Attention-Deficit Disorder (ADD) or Attention-Deficit Hyperactivity Disorder (ADHD) and
- Client must be over the age of 4, and
- Client must have had a trial and failure of a stimulant greater than or equal to a 14 day supply OR a trial and failure of Strattera greater than or equal to a 30 day supply AND a trial, WITH BENEFIT, of guanfacine IR greater than or equal to a 14 day supply, all within the last year, or
- A contraindication to ADD/ADHD medications, or
- A tic disorder.

Please contact the GHS pharmacy help desk at 877-209-1264 with any questions regarding this change.

PROVIDER ACCESS SURVEY

As part of Wyoming Medicaid's efforts to assess our clients' access to covered Medicaid Services, we have developed a survey for providers to share their thoughts on this issue. We would greatly appreciate pharmacy providers' participation in this survey. We ask that pharmacy providers submit one survey per enrolled pharmacy location. In order to ensure your answers are part of the final analysis, we ask that you respond to the survey no later than February 29, 2016. Thank you so much for your time in completing this survey and for your continued care of Wyoming Medicaid patients. Please visit the following web address to complete the survey.

<https://www.surveymonkey.com/r/MedicaidProviderAccessSurvey2016>